Resources
Impact of switching antiplatelet therapy in acute coronary syndrome patients with different CYP2C19 phenotypes: insights from a single-center study
Nagendra Boopathy Senguttuvan, Muralidharan Thoddi Ramamurthy, Nithesh Kumar, Pavitraa Saravana Kumar, Yogapriya Chidambaram, Madhesh Kasi, Gautam Ganesan Karthikeyan, Asuwin Anandaram, Bharath Raj Kidambi, Sadhanandham Shanmugasundram, Manokar Panchanatham, Rammurthy Anjanappa, Venu Seenappa, Vettriselvi Venkatesan, Ramesh Sankaran, Thanikachalam Sadagopan
Pharmacogenet Genomics. 21 Mar, 2025
PMID: 40112230
Optimizing antiplatelet therapy is crucial in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary interventions (PCIs). This study aimed to assess the prevalence of CYP2C19 loss-of-function (LOF) variants and evaluate the clinical outcome of ticagrelor, clopidogrel, and aspirin in patients with ACS-PCI.
Company
Resources
Research
- Tumor Microenvironment Solutions
- Immune Profiling Services
- NGS Services
- BioFX Bioinformatics Services
- Antibody Discovery Services
Diagnostics
Contact